Pardes expects to launch a major trial of COVID-19 antiviral pill by the middle of the year
Pardes expects to launch a major trial of COVID-19 antiviral pill by the middle of the year

Pardes expects to launch a major trial of COVID-19 antiviral pill by the middle of the year

February 14 (Reuters) – Pardes Biosciences Inc (PRDS.O) said Monday that it expects to launch a mid-to-late-stage trial of its experimental COVID-19 antiviral pill by the middle of the year, according to promising data from early human tests.

Preliminary data from an ongoing early-stage trial have shown that a twice-daily intake of the pill, PBI-0451, could trigger potent antiviral activity against SARS-CoV-2 and its new variants, Pardes said.

The drug was well tolerated and all side effects reported so far have been assessed as mild in severity and resolved without intervention, the company added.

Sign up now for FREE unlimited access to Reuters.com

The Pardes drug is a protease inhibitor, designed to prevent coronavirus from replicating in human cells. It’s the same class of medicine as Pfizers (PFE.N) nirmatrelvir.

When used in combination with Pfizer’s antiviral ritonavir, nirmatrelvir was shown to reduce the risk of hospitalization or death by 89% for COVID-19 patients at high risk of serious disease.

Pardes said its drug has the potential to be a stand-alone treatment, unlike drugs like Pfizer’s two-dose antiviral drug Paxlovid, which must be taken with another booster drug.

Sign up now for FREE unlimited access to Reuters.com

Reporting of Mrinalika Roy in Bengaluru; Editing Devika Syamnath

Our standards: Thomson Reuters trust principles.

Leave a Reply

Your email address will not be published.